Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033735 · ClinicalTrials.gov registry record · Phase 3
Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer
A Phase 3 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 3
- Development phase
- 158
- Enrollment target
NCT00033735 is a Phase 3 study that has completed, run by Eisai. The registered enrollment target is 158 participants.
The verdict
NCT00033735, a Phase 3 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 158 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether irofulven is effective in treating pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of irofulven with that of fluorouracil in treating patients who have locally advanced or metastatic pancreatic cancer that has not responded to previous treatment with gemcitabine.
Interventions
- DRUG fluorouracil
- DRUG Irofulven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2000-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00033735
The ClinicalTrials.gov registry entry for NCT00033735 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which fluorouracil is the first listed.
NCT00033735 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00033735 about?
NCT00033735 is a clinical study titled "Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether irofulven is effective in treating pancreatic cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of irofulven with that of fluoro...
What is the current status of trial NCT00033735?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 158 participants. The study started on 2000-01.
What interventions are being tested in trial NCT00033735?
The interventions under investigation include: fluorouracil (DRUG), Irofulven (DRUG).
Who is sponsoring clinical trial NCT00033735?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.